Printer Friendly

UNIVERSITY OF MINNESOTA AND ENDOTRONICS, INC. TO COLLABORATE ON DEVELOPMENT OF BIO-ARTIFICIAL DEVICE TO REPLACE LIVER FUNCTION

 UNIVERSITY OF MINNESOTA AND ENDOTRONICS, INC. TO COLLABORATE
 ON DEVELOPMENT OF BIO-ARTIFICIAL DEVICE TO REPLACE LIVER FUNCTION
 MINNEAPOLIS, Dec. 19 /PRNewswire/ -- The University of Minnesota and Endotronics, Inc. (NASDAQ: ENDO) jointly announced today an agreement with the University of Minnesota's Office of Research and Technology Transfer to pursue research, development and commercialization of a bio- artificial liver (BAL) device to provide short-term extracorporeal support for patients in liver failure.
 Under the terms of the agreement, Endotronics will finance a $650,000 three-year project to pursue further research, development and commercialization of the BAL technology. The basic technology was developed by a team of University of Minnesota researchers led by Dr. Frank Cerra, M.D., professor of surgery and director of trauma and clinical care services at the University of Minnesota Hospital and Clinic, and Dr. Wei-Shou Hu, associate professor of chemical engineering in the Department of Chemical Engineering and Materials Science.
 Richard Sakowicz, Endotronics president and chief operating officer, said, "We are very pleased to announce this important collaboration with the University of Minnesota. The primary focus of the BAL project is to make the BAL a bridge device for two types of patients, those who suffer from acute liver injury and need temporary support or those with irreversible injury needing liver support until transplantation. The BAL technology developed at the University of Minnesota has the potential to satisfy that need."
 "The BAL project is an important step in the implementation of our strategic plan enabling us to apply our biomedical engineering and cell culture expertise directly into the field of human health care," Sakowicz said.
 Development of the BAL will be followed by human clinical trials required to gain clearance from the U.S. Food and Drug Administration (FDA) to market the product. Human clinical trials are expected to begin within two to three years. Under the terms of the agreement, Endotronics will acquire the rights to manufacture and market the BAL device following FDA approval.
 Endotronics, Inc., headquartered in Minneapolis, is a recognized industry leader in hollow fiber cell culture instrumentation. The company's products and services are used by biotechnology, pharmaceutical, diagnostic and research centers worldwide for the production of mammalian cell-derived human health-care products.
 -0- 12/19/91
 /CONTACT: Yvonne L. Marschner-Bova of Endotronics, Inc., 313-871-7350; or Mike Moore of the Office of Research and Technology Transfer, University of Minnesota, 612-624-9398/
 (ENDO) CO: Endotronics, Inc.; University of Minnesota ST: Michigan, Minnesota IN: MTC SU: FNC


DH -- DE026 -- 4064 12/19/91 16:07 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 19, 1991
Words:417
Previous Article:SCIMED ANNOUNCES THIRD QUARTER RESULTS
Next Article:SANTA FE PACIFIC PIPELINE PARTNERS L.P. ANNOUNCES CALIFORNIA INTRASTATE RATE INCREASE
Topics:


Related Articles
ENDOTRONICS, INC. INTRODUCES ACUMOUSE CELL CULTURE INSTRUMENT -- COST-EFFECTIVE SUBSTITUTE FOR LABORATORY MICE
ENDOTRONICS DISCONTINUES DISTRIBUTION AGREEMENT WITH VENTREX LABORATORIES -- SIGNS LETTER OF INTENT WITH NORTHUMBRIA BIOLOGICALS
ENDOTRONICS, INC. RECEIVES U.S. PATENT ON SCALABLE OXYCELL CELL CULTURE TECHNOLOGY
ENDOTRONICS, INC. REPORTS RESULTS FOR FIRST QUARTER ENDED DEC. 31, 1991
ENDOTRONICS SIGNS PRODUCTION AND MARKETING AGREEMENT WITH HELIXYS
ENDOTRONICS, INC. CONFIRMS SCIENTIFIC ADVISORY BOARD FOR BIO-ARTIFICIAL LIVER PROJECT
ENDOTRONICS, INC. AGREES TO PURCHASE VERAX PRODUCT LINE
REGENEREX, INC. APPOINTS PRESIDENT, COO TO LEAD DEVELOPMENT PROGRAM FOR ARTIFICIAL LIVER
PITT MEDICAL CENTER BEGINS TRIAL OF ARTIFICIAL LIVER
HEPALIFE COLLABORATES WITH USDA ON LIVER STORAGE RESULTS.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters